Patents by Inventor Hajimu Kurumatani
Hajimu Kurumatani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230022200Abstract: A method of preventing dialysis shift or renal death includes administering to a primary glomerular disease or nephrosclerosis patient with a serum creatinine level of 2.0 mg/dl or more and less than 3.0 mg/dl a sustained-release preparation including, as an active ingredient, a compound represented by formula (I): wherein R represents hydrogen or a pharmacologically acceptable cation, such that the compound represented by formula (I) is administered at 220 to 260 ?g per day.Type: ApplicationFiled: December 23, 2020Publication date: January 26, 2023Inventors: Hajimu Kurumatani, Kiyonobu Okada, Naohiro Yamada, Takashi Kiriyama, Hiroyuki Kano, Shunsuke Yamada
-
Publication number: 20220096707Abstract: A hemostatic material includes a lipid that can accelerate adhesion or aggregation of platelets even if the lipid does not carry a protein or a peptide involved in adhesion or aggregation of platelets such as GPIb and H12 and, to achieve the object, provides a hemostatic material including a water-insoluble base and a lipid supported on a surface of the base, wherein the lipid includes one or two or more anionic lipids.Type: ApplicationFiled: October 17, 2019Publication date: March 31, 2022Applicant: Toray Industries, Inc.Inventors: Shinji Takeoka, Keiko Nakahara, Mamoru Nishiura, Shinya Otsubo, Hajimu Kurumatani, Toru Arakane, Masanobu Takeda, Makoto Nakahara, Kumi Oyama
-
Publication number: 20210387943Abstract: A carboxylic acid-type lipid can accelerate adhesion or aggregation of platelets even if the carboxylic acid-type lipid does not carry a protein involved in adhesion or aggregation of platelets or a peptide corresponding to an active site of the protein; a lipid particle and a lipid membrane each include the carboxylic acid-type lipid; and a platelet aggregation accelerating agent, a platelet adhesion accelerating agent, a hemostatic agent and a platelet substitute each include the carboxylic acid-type lipid, the lipid particle or the lipid membrane. A carboxylic acid-type lipid is selected from carboxylic acid-type lipids represented by formulas (I) to (VI), a lipid particle includes the carboxylic acid-type lipid, a lipid membrane includes the carboxylic acid-type lipid, and a platelet aggregation accelerating agent, a platelet adhesion accelerating agent, a hemostatic agent and a platelet substitute each include the carboxylic acid-type lipid, the lipid particle or the lipid membrane.Type: ApplicationFiled: October 17, 2019Publication date: December 16, 2021Inventors: Shinji Takeoka, Keiko Nakahara, Mamoru Nishiura, Shinya Otsubo, Hajimu Kurumatani, Toru Arakane
-
Patent number: 10149909Abstract: An agent enhances the therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases, including a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.Type: GrantFiled: December 7, 2016Date of Patent: December 11, 2018Assignee: Toray Industries, Inc.Inventors: Hajimu Kurumatani, Mitsutaka Tamura
-
Patent number: 9913825Abstract: A method of ameliorating symptoms of uremia includes administering a therapeutic agent including beraprost or each isomer constituting beraprost, or a salt thereof as an effective ingredient to an animal belonging to the Family Canidae, wherein an effective dosage is a dosage that does not significantly lower blood pressure.Type: GrantFiled: April 27, 2017Date of Patent: March 13, 2018Assignee: Toray Industries, Inc.Inventors: Masahiko Takenaka, Yoshihisa Yamane, Nobutaka Ida, Hajimu Kurumatani
-
Patent number: 9783518Abstract: A therapeutic agent and a treatment method for uremia of human and animals, which therapeutic agent can be easily taken, has lower side effects, and which is not expensive in view of medical economics, are disclosed. The therapeutic agent for uremia in patients suffering from chronic renal failure comprises as an effective ingredient a prostaglandin I2 derivative having a specific structure, such as beraprost sodium. The therapeutic agent for uremia ameliorates the uremia concurred in patients with chronic renal failure without accompanying side effects, and restoration of decreased appetite, improvements in activities, increase in body weight and the like are achieved. The therapeutic effect of uremia is clear alleviation or disappearance of symptoms of uremia grasped as clinical symptoms, observed in the state of renal failure, especially even in spite of the state wherein the decrease in renal function is progressed.Type: GrantFiled: July 7, 2006Date of Patent: October 10, 2017Assignee: Toray Industries, Inc.Inventors: Masahiko Takenaka, Yoshihisa Yamane, Nobutaka Ida, Hajimu Kurumatani
-
Publication number: 20170224652Abstract: A method of ameliorating symptoms of uremia includes administering a therapeutic agent including beraprost or each isomer constituting beraprost, or a salt thereof as an effective ingredient to an animal belonging to the Family Canidae, wherein an effective dosage is a dosage that does not significantly lower blood pressure.Type: ApplicationFiled: April 27, 2017Publication date: August 10, 2017Inventors: Masahiko Takenaka, Yoshihisa Yamane, Nobutaka Ida, Hajimu Kurumatani
-
Publication number: 20170080089Abstract: An agent enhances the therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases, including a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.Type: ApplicationFiled: December 7, 2016Publication date: March 23, 2017Inventors: Hajimu Kurumatani, Mitsutaka Tamura
-
Patent number: 9546145Abstract: An agent for enhancing therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases is disclosed, including a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.Type: GrantFiled: March 12, 2009Date of Patent: January 17, 2017Assignee: Toray Industries, Inc.Inventors: Hajimu Kurumatani, Mitsutaka Tamura
-
Patent number: 9457032Abstract: A therapeutic agent for renal failure including, as an active ingredient, a 4,8-inter-m-phenylene prostaglandin I2 derivative, and also a method for treatment of renal failure using the same.Type: GrantFiled: February 10, 2009Date of Patent: October 4, 2016Assignee: Toray Industries, Inc.Inventors: Hajimu Kurumatani, Motohiro Suzuki
-
Patent number: 8575175Abstract: The present invention aims to provide a therapeutic agent for chronic renal failure, comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof. That is, the present invention provides provision of a drug comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof, which drug is useful not only for amelioration of renal function, but also for amelioration of anemia, activation of SOD and excretion of uremic substances.Type: GrantFiled: July 23, 2009Date of Patent: November 5, 2013Assignee: Toray Industries, Inc.Inventors: Fuko Matsuda, Katsuhiko Iseki, Hajimu Kurumatani, Mitsuko Miyamoto
-
Publication number: 20110178103Abstract: The present invention aims to provide a therapeutic agent for chronic renal failure, comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof. That is, the present invention provides provision of a drug comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof, which drug is useful not only for amelioration of renal function, but also for amelioration of anemia, activation of SOD and excretion of uremic substances.Type: ApplicationFiled: July 23, 2009Publication date: July 21, 2011Applicant: TORAY INDUSTRIES, INC.Inventors: Fuko Matsuda, Katsuhiko Iseki, Hajimu Kurumatani, Mitsuko Miyamoto
-
Publication number: 20090176848Abstract: An agent for enhancing therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases is disclosed, including a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.Type: ApplicationFiled: March 12, 2009Publication date: July 9, 2009Applicant: Toray Industries, Inc., a corporation of JapanInventors: Hajimu Kurumatani, Mitsutaka Tamura
-
Publication number: 20090163584Abstract: A therapeutic agent for renal failure including, as an active ingredient, a 4,8-inter-m-phenylene prostaglandin I2 derivative, and also a method for treatment of renal failure using the same.Type: ApplicationFiled: February 10, 2009Publication date: June 25, 2009Applicant: Toray Industries, Inc., a corporation of JapanInventors: Hajimu Kurumatani, Motohiro Suzuki
-
Publication number: 20090143463Abstract: A therapeutic agent and a treatment method for uremia of human and animals, which therapeutic agent can be easily taken, has lower side effects, and which is not expensive in view of medical economics, are disclosed. The therapeutic agent for uremia in patients suffering from chronic renal failure comprises as an effective ingredient a prostaglandin I2 derivative having a specific structure, such as beraprost sodium. The therapeutic agent for uremia ameliorates the uremia concurred in patients with chronic renal failure without accompanying side effects, and restoration of decreased appetite, improvements in activities, increase in body weight and the like are achieved. The therapeutic effect of uremia is clear alleviation or disappearance of symptoms of uremia grasped as clinical symptoms, observed in the state of renal failure, especially even in spite of the state wherein the decrease in renal function is progressed.Type: ApplicationFiled: July 7, 2006Publication date: June 4, 2009Applicant: Toray Industries, Inc., a corporation of JapanInventors: Masahiko Takenaka, Yoshihisa Yamane, Nobutaka Ida, Hajimu Kurumatani
-
Publication number: 20080269155Abstract: A novel agent for therapy and/or prevention of kidney diseases as well as a diagnostic method (detection method) of kidney diseases is disclosed. The agent for therapy and/or prevention of kidney diseases comprises as an effective ingredient a substance which inhibits casein kinase 2. The diagnostic method of kidney diseases according to the present invention comprises measuring activity or content of casein kinase 2, or measuring expression amount of casein kinase 2 gene in a sample separated from body.Type: ApplicationFiled: March 17, 2008Publication date: October 30, 2008Applicant: TORAY INDUSTRIES INC.Inventors: Masateru Yamada, Hajimu Kurumatani, Tetsuo Sudo, Gozoh Tsujimoto
-
Publication number: 20060293256Abstract: A novel agent for therapy and/or prevention of kidney diseases as well as a diagnostic method (detection method) of kidney diseases is disclosed. The agent for therapy and/or prevention of kidney diseases comprises as an effective ingredient a substance which inhibits casein kinase 2. The diagnostic method of kidney diseases according to the present invention comprises measuring activity or content of casein kinase 2, or measuring expression amount of casein kinase 2 gene in a sample separated from body.Type: ApplicationFiled: August 5, 2003Publication date: December 28, 2006Inventors: Masateru Yamada, Hajimu Kurumatani, Tetsuo Sudo
-
Publication number: 20060217421Abstract: An agent for enhancing therapeutic or prophylactic effect of administering an inhibitor of renin-angiotensin system, such as candesartan cilexetil, on renal diseases is disclosed. The agent comprises a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.Type: ApplicationFiled: May 6, 2004Publication date: September 28, 2006Inventors: Hajimu Kurumatani, Mitsutaka Tamura
-
Publication number: 20060106095Abstract: The present invention relates to a therapeutic agent for renal failure comprising, as an active ingredient, a 4,8-inter-m-phenylene prostaglandin I2 derivative, and also relates to a method for treatment of renal failure using the same.Type: ApplicationFiled: December 28, 2005Publication date: May 18, 2006Applicant: Toray Industries, Inc., a corporation of JapanInventors: Hajimu Kurumatani, Motohiro Suzuki
-
Patent number: 6653345Abstract: A method of inhibiting mammalian C—C chemokine production by using a mammalian C—C chemokine synthesis inhibitor containing a prostaglandin I derivative as an active component to treat a variety of circulatory diseases, inflammation, allergic diseases, and renal diseases.Type: GrantFiled: May 6, 2002Date of Patent: November 25, 2003Assignee: Toray Industries, Inc.Inventors: Hajimu Kurumatani, Rie Sasaki, Hiroki Kumagai